Quantbot Technologies LP Has $1.79 Million Stock Holdings in Collegium Pharmaceutical, Inc. $COLL

Quantbot Technologies LP increased its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 380.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 51,236 shares of the specialty pharmaceutical company’s stock after acquiring an additional 40,567 shares during the period. Quantbot Technologies LP’s holdings in Collegium Pharmaceutical were worth $1,793,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in COLL. Bank of New York Mellon Corp increased its stake in shares of Collegium Pharmaceutical by 3.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 249,875 shares of the specialty pharmaceutical company’s stock valued at $7,389,000 after acquiring an additional 7,614 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Collegium Pharmaceutical by 90.5% in the third quarter. Assenagon Asset Management S.A. now owns 195,589 shares of the specialty pharmaceutical company’s stock worth $6,844,000 after purchasing an additional 92,898 shares during the period. Ballast Asset Management LP increased its stake in Collegium Pharmaceutical by 31.1% in the third quarter. Ballast Asset Management LP now owns 114,315 shares of the specialty pharmaceutical company’s stock valued at $4,000,000 after purchasing an additional 27,109 shares in the last quarter. Versor Investments LP bought a new stake in Collegium Pharmaceutical in the third quarter valued at $1,337,000. Finally, Eastern Bank raised its holdings in shares of Collegium Pharmaceutical by 487.5% during the third quarter. Eastern Bank now owns 54,843 shares of the specialty pharmaceutical company’s stock valued at $1,919,000 after purchasing an additional 45,508 shares during the period.

Analyst Ratings Changes

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Barclays cut their target price on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a report on Friday, January 9th. Finally, Needham & Company LLC decreased their price target on shares of Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $53.00.

Collegium Pharmaceutical Stock Down 1.0%

COLL stock opened at $39.61 on Thursday. The firm has a market capitalization of $1.26 billion, a PE ratio of 23.16 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.57 and a debt-to-equity ratio of 2.59. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $50.79. The stock’s 50 day moving average is $45.98 and its 200-day moving average is $42.12.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The company had revenue of $205.45 million for the quarter, compared to the consensus estimate of $206.36 million. During the same quarter last year, the company posted $1.77 EPS. The company’s quarterly revenue was up 12.9% compared to the same quarter last year. Sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 17,600 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the completion of the sale, the executive vice president directly owned 103,613 shares of the company’s stock, valued at approximately $4,991,038.21. This represents a 14.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the sale, the director owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. This trade represents a 6.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.